I

IC La Serena Research | La Serena, Chile

Research site
(Unclaimed)
Location
Woodrow Wilson 1697, La Serena, Coquimbo, Chile

Site insights

Top conditions

Top treatments

Pembrolizumab
Nemtabrutinib
Gemcitabine
Bintrafusp Alfa
ACE-536
M7824
Luspatercept
MK-1026-008
Bemarituzumab
Venetoclax

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 13 total trials

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in partici...

Enrolling
CLL
Small-Cell Lymphoma
Drug: Nemtabrutinib
Biological: Rituximab

The purpose of this study is to evaluate the efficacy and safety of nemtabrutinib compared to investigator's choice of fludarabine plus cyclophospham...

Enrolling
Small Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Drug: Bendamustine
Drug: Cyclophosphamide
Locations recently updated

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with sel...

Enrolling
Follicular Lymphoma
Mantle Cell Lymphoma
Biological: Zilovertamab vedotin
Drug: Nemtabrutinib

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Other: Placebo
Drug: Deucravacitinib

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Enrolling
Anemia
Myelofibrosis
Other: Placebo
Drug: ACE-536

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS)...

Enrolling
Non-Small-Cell Lung Carcinoma
Lung Neoplasms
Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypo...

Enrolling
Systemic Lupus Erythematosus
Biological: MK-6194
Biological: Placebo

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalut...

Active, not recruiting
Metastatic Hormone-Sensitive Prostate Cancer
Drug: Androgen Deprivation Therapy (ADT)
Other: Placebo

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after in...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine
Locations recently updated

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metas...

Enrolling
Prostate Cancer Metastatic
Drug: Dexamethasone
Drug: Hydrocortisone

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the...

Enrolling
Melanoma
Drug: Lenvatinib
Biological: Vibostolimab

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
Merck KGaA (EMD Serono) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems